Summary characteristics of participants in the studies included in the meta-analysis
| . | LMWH (n = 425) . | No LMWH (n = 423) . | Combined (n = 848) . | |
|---|---|---|---|---|
| n/N . | n/N . | n/N . | % . | |
| Thrombophilia | 106/425 | 107/423 | 213/848 | 25 |
| Prior PE | 296/425 | 293/423 | 593/848 | 70 |
| Prior severe PE | 208/304 | 208/304 | 416/608 | 68 |
| Prior SGA <10th percentile | 76/192 | 67/192 | 143/384 | 37 |
| Prior abruption | 91/192 | 90/203 | 181/405 | 45 |
| Prior loss >12 wk | 34/122 | 32/123 | 66/245 | 27 |
| Concomitant ASA use | 178/495 | 260/423 | 438/848 | 52 |
| . | LMWH (n = 425) . | No LMWH (n = 423) . | Combined (n = 848) . | |
|---|---|---|---|---|
| n/N . | n/N . | n/N . | % . | |
| Thrombophilia | 106/425 | 107/423 | 213/848 | 25 |
| Prior PE | 296/425 | 293/423 | 593/848 | 70 |
| Prior severe PE | 208/304 | 208/304 | 416/608 | 68 |
| Prior SGA <10th percentile | 76/192 | 67/192 | 143/384 | 37 |
| Prior abruption | 91/192 | 90/203 | 181/405 | 45 |
| Prior loss >12 wk | 34/122 | 32/123 | 66/245 | 27 |
| Concomitant ASA use | 178/495 | 260/423 | 438/848 | 52 |
n/N, number (n) with characteristic/total number (N) in treatment group.